Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Ascites, and Prolong Survival in an in vivo Ovarian Cancer Model

• Li Wang ,

  * E-mail: wangli1672003@yahoo.com.cn (LW) (LW); y.li@unsw.edu.au (YL) (YL)

  Affiliations Department of Gynecologic Oncology, Henan Cancer Hospital, Zhengzhou, Henan, China, Faculty of Medicine, University of New South Wales, Sydney, Australia

  ⨯
• Hongmin Chen,

  Affiliations Department of Gynecologic Oncology, Henan Cancer Hospital, Zhengzhou, Henan, China, Faculty of Medicine, University of New South Wales, Sydney, Australia

  ⨯
• Mohammad H. Pourgholami,

  Affiliations Faculty of Medicine, University of New South Wales, Sydney, Australia, Department of Surgery, St George Hospital, Sydney, Australia

  ⨯
• Julia Beretov,

  Affiliations Faculty of Medicine, University of New South Wales, Sydney, Australia, Cancer Care Centre, St George Hospital, Sydney, Australia, Anatomical Pathology, St George Hospital, Sydney, Australia

  ⨯
• Jingli Hao,

  Affiliations Faculty of Medicine, University of New South Wales, Sydney, Australia, Cancer Care Centre, St George Hospital, Sydney, Australia

  ⨯
• Hongtu Chao,

  Affiliations Department of Gynecologic Oncology, Henan Cancer Hospital, Zhengzhou, Henan, China, Faculty of Medicine, University of New South Wales, Sydney, Australia

  ⨯
• Alan C. Perkins,

  Affiliation Academic Medical Physics, Medical School, Queen's Medical Centre, Nottingham, United Kingdom

  ⨯
• John H. Kearsley,

  Affiliations Faculty of Medicine, University of New South Wales, Sydney, Australia, Cancer Care Centre, St George Hospital, Sydney, Australia

  ⨯
• Yong Li

  * E-mail: wangli1672003@yahoo.com.cn (LW) (LW); y.li@unsw.edu.au (YL) (YL)

  Affiliations Faculty of Medicine, University of New South Wales, Sydney, Australia, Cancer Care Centre, St George Hospital, Sydney, Australia

  ⨯